Health Care Fund
Daily price w/o sales charge as of 08/23/2019
$14.40
$0.26
Please click here for performance current to the most recent quarter-end and month-end.
Summary
Summary
The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.
Fund Basics
- Total Net Assets
- -
- Inception Date
- 08/01/2019
- Dividend Frequency
- Monthly (Daily Accrual)
- Fund Gross Expense Ratio
- 0.96%
- Fund Net Expense Ratio
- 0.78%
- Number of Holdings
- -
Fund Expense Ratio :
Gross 0.96%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | - | - | - | - | - | 0.00% |
| Lipper Category Avg. Health/Biotechnology Funds | - | - | - | - | - | - |
Performance data for the Lipper Category Average and for the Index is shown as soon as it becomes available.
Fund Expense Ratio :
Gross 0.96%
Net 0.78%
Fund Expense Ratio :
Gross 0.96%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | - | - | - | - | - | - |
| Lipper Category Avg. Health/Biotechnology Funds | - | - | - | - | - | - |
Performance data for the Lipper Category Average and for the Index is shown as soon as it becomes available.
Fund Expense Ratio :
Gross 0.96%
Net 0.78%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
Returns with sales charge reflect a maximum sales charge of 5.75%
INVESTMENT TEAM
Contact a Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 0.96%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | - | - | - | - | - | 0.00% |
| Lipper Category Avg. Health/Biotechnology Funds | - | - | - | - | - | - |
Performance data for the Lipper Category Average and for the Index is shown as soon as it becomes available.
Fund Expense Ratio :
Gross 0.96%
Net 0.78%
Fund Expense Ratio :
Gross 0.96%
Net 0.78%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
|---|
| w/o sales charge | - | - | - | - | - | - |
| Lipper Category Avg. Health/Biotechnology Funds | - | - | - | - | - | - |
Performance data for the Lipper Category Average and for the Index is shown as soon as it becomes available.
Fund Expense Ratio :
Gross 0.96%
Net 0.78%
NAV Historical Prices
| Date | Net Asset Value |
|---|
Fees & Expenses
Fees & Expenses
Expense Ratioas of 07/31/2019
| Fund Gross Expense Ratio | Fund Net Expense Ratio | |
|---|---|---|
| 0.96% | 0.78% |
Expense ratio details, Click here.
The net expense ratio is based on estimates for the current fiscal year and takes into account contractual fee waivers/expense reimbursements that currently are scheduled to remain in place through 02/28/2021. For periods when fees and expenses were waived and/or reimbursed, the Fund benefited by not bearing such expenses. Without such fee waivers/reimbursements, performance would have been lower.
Fund Documents
Fund Documents
Download fund documents & literature, create email subscriptions, and place direct mail order
|
0Documents selected
|
Order | ||||
|---|---|---|---|---|---|
|
Summary Prospectus
Publish Date:11/03/2015
|
|||||
| n/a |
Statutory Prospectus
Publish Date:11/03/2015
|
||||
| n/a |
Prospectus (XBRL)
Publish Date:11/03/2015
|
||||
|
SAI
Publish Date:11/03/2015
|
|||||